Pipeline and Programs Overview

Incannex is leading the way in developing combination therapeutics that target underlying biological pathways associated with disease. We are applying this innovative approach to address a range of conditions, including obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder, with the goal of delivering more effective treatments for patients in need.

swipe
img

IHL-42X

Obstructive Sleep Apnea

  • RePOSA

    Ph 2/3 Safety & Efficacy Trial
    • 560-patient, randomized, double-blind safety and efficacy study
    • Dosing started May 2024

  • BA/BE

    Bioavailability Trial
    • 115-subject, bioavailability and bioequivalence study
    • Dosing completed July 2024

  • POC

    Ph 2 Trial
    • Crossover, safety and efficacy study
    • Study completed
img

IHL-675A

Rheumatoid Arthritis

  • Phase 2

    Ph 2 Safety and Efficacy Study
    • 128-patient, double-blind, safety and efficacy study
    • Dosing started January 2024

  • Phase 1

    Ph 1 Safety and PK Study
    • 36-patient, Phase 1 safety and PK study
    • Study completed
img

PSX-001

Generalized Anxiety Disorder

  • PsiGAD2

    Ph 2 Dose Comparison
    • 94-patient, double-blind, safety and efficacy study

  • PsiGAD1

    Ph 2 Trial
    • 73-patient, double-blind, safety and efficacy study
    • Dosing completed January 2024

Patients

img
smiling black male patient smiling black male patient
Patients

We are working urgently to develop innovative therapies for patients with obstructive sleep apnea (OSA), rheumatoid arthritis (RA), and generalized anxiety disorder (GAD).

Explore Incannex’s active clinical trials and learn more about the opportunity to participate.

Learn More img

IHL-42X

IHL-675A

PSX-001

Get in touch to learn more about our programs and to receive updates.

Contact Us img